DP-VPA for Migraine Prophylaxis, a Pilot Efficacy Study - Full Text View

Sponsored by:	D-Pharm Ltd.
Information provided by:	D-Pharm Ltd.
ClinicalTrials.gov Identifier:	NCT00640965

Purpose

The study will evaluate if DP-VPA, a derivative of valproate (a drug that is commonly used for the prevention of migraine attacks), can reduce the rate of migraine attacks.

Migraine patients will take DP-VPA or placebo (an inactive look-alike drug) every morning and will have to report any migraine attacks they have during the study's 18-week follow up.

Condition	Intervention	Phase
Migraine	Drug: DP-VPA Drug: DP-VPA Placebo	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Two-Arm, Multi-Center Phase II Trial to Assess the Safety, Tolerability, and Efficacy of DP-VPA (up to 900 mg) Once Daily for 10 Weeks in Adult Subjects With Migraine

Resource links provided by NLM:

Genetics Home Reference related topics: familial hemiplegic migraine

MedlinePlus related topics: Migraine

U.S. FDA Resources

Further study details as provided by D-Pharm Ltd.:

Primary Outcome Measures:

Migraine attacks frequency [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Migraine days [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Responders (subjects with >50% decrease in migraine frequency) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Triptan consumption [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment:	40
Study Start Date:	July 2008
Estimated Study Completion Date:	August 2009
Estimated Primary Completion Date:	June 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
A: Experimental DP-VPA	Drug: DP-VPA DP-VPA dose escalation to 900mg, then continued for 8 weeks
B: Placebo Comparator	Drug: DP-VPA Placebo Matching Placebo to Active, dose escalation, then continued for 8 weeks

Detailed Description:

The multi-center trial has a double-blind, randomized, placebo-controlled, parallel-group design and will be carried out in Israel. Approximately 40 adult subjects with migraine will be randomly assigned (1:1) to either DP-VPA (maximum of 900mg/day) or placebo. Active and placebo will be administered orally and once-daily on an add-on basis, i.e. other permissible ongoing medications will be continued. Total study duration per subject will be 18 weeks. Subjects will report on their migraine attacks frequency and other attack characteristics using weekly diaries.

Eligibility

Ages Eligible for Study:	18 Years to 85 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria (abridged)

Male and female subjects with migraine with or without aura fulfilling the diagnostic criteria of the International Classification of Headache Disorders
3 to 6 migraine attacks per month
Concomitant prophylactic migraine treatment with a beta-blocker or amitriptyline that has been stable in the proceeding 3 months. No changes in this concomitant treatment will be allowed until the end of study follow-up.

Exclusion criteria (abridged)Chronic migraine (>15 days of migraine/ month).

Migraine complicated by medication-overuse headache.
Allergy or hypersensitivity to valproic acid, valproate sodium, or soy.
Known contraindications to valproic acid.
Pregnancy.
Breastfeeding female subjects.
Subjects with significant hepatic dysfunction indicated by SGOT or SGPT >3 times the upper limit of normal at screening.
Renal impairment indicated by serum creatinine >1.5mg/dL at screening.
Potentially fertile and sexually active women who do not practice reliable contraception.
Men who do not practice reliable barrier contraception.
Concomitant use of antipsychotic, antidepressant or antiepileptic therapy - with the exception of amitriptyline - within 1 month of screening, or a medical condition that is likely to require such treatment during the trial participation.
An active central nervous system disease deemed to be unstable or progressive during the course of the study that may confound the interpretation of the study results.
Any medical disorder that may makes the subject unlikely to fully complete the study- Blood coagulation disorder.
Concomitant drugs known to interact with VPA.- Alcohol or other drugs abuse.
Therapy with another investigational product within 30 days prior start of study.
Concomitant participation in another trial or study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00640965

Locations

Israel
Chaim Sheba Medical Center
Tel Hashomer, Israel, 52621
Rambam Medical Center
Haifa, Israel, 31096
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel, 64239
Beilinson Medical Centre
Petah Tikva, Israel
Bnei Zion Medical Centre
Haifa, Israel
Wolfson Medical Center
Holon, Israel, 58220

Sponsors and Collaborators

D-Pharm Ltd.

Investigators

Study Director:

Gilad Rosenberg, M.D.

D-Pharm Ltd.

More Information

No publications provided

Responsible Party:	D-Pharm Ltd. ( Dr. Gilad Rosenberg )
Study ID Numbers:	Ptcl-01325
Study First Received:	March 17, 2008
Last Updated:	May 4, 2009
ClinicalTrials.gov Identifier:	NCT00640965 History of Changes
Health Authority:	Israel: Health Ministry, Pharmaceutical Administration

Study placed in the following topic categories:

Migraine Disorders
Headache
Central Nervous System Diseases

Headache Disorders, Primary
Brain Diseases
Headache Disorders

Additional relevant MeSH terms:

Migraine Disorders
Nervous System Diseases
Central Nervous System Diseases

Headache Disorders, Primary
Brain Diseases
Headache Disorders

ClinicalTrials.gov processed this record on September 10, 2009